GlassScriptPhysician profile
Robert J Pearlstein
NPI 1598788689
$14,745.10
in general payments reported to CMS, 2019-2025
87 companies · $1,653 in 2025
The $1,653 reported for 2025 was more than what 94% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2020: $1,420 · 2021: $2,998 · 2022: $2,351 · 2023: $2,543 · 2024: $1,506 · 2025: $1,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,659 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,658.96 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,274.16 | 2019-2022 | |
| Pfizer INC. | $1,246.00 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,057.95 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Acadia Pharmaceuticals INC | $962.32 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $886.61 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $578.23 | 2019-2025 | Nayzilam, Briviact |
| Lilly USA, LLC | $532.80 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Astrazeneca Pharmaceuticals LP | $528.61 | 2019-2025 | Farxiga, Breztri, Wainua |
| Sumitomo Pharma America, INC. | $510.92 | 2023-2025 | Aptiom, Gemtesa |
| Avanir Pharmaceuticals, INC. | $439.45 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $373.99 | 2019-2025 | Invega Sustenna, Invega Trinza, Xarelto |
| Biogen, INC. | $339.91 | 2019-2023 | Spinraza |
| Astellas Pharma US INC | $324.77 | 2019-2023 | Myrbetriq |
| Novartis Pharmaceuticals Corporation | $322.86 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $318.64 | 2020-2025 | Ingrezza, Ongentys |
Show all 86 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pearlstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.